Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold Pharmaceuticals has received an orphan drug designation for TH-302, to treat of soft tissue sarcoma, from the European Commission.
Subscribe to our email newsletter
The company is conducting a pivotal Phase III study in soft tissue sarcoma comparing TH-302 in combination with doxorubicin against single agent doxorubicin.
The same combination regimen of TH-302, a hypoxia-targeted drug, with doxorubicin was investigated in the single-arm Phase 2 (TH-CR-403) study.
Threshold CEO Barry Selick said TH-302 was designed to selectively target hypoxic regions within tumors, which are believed to not be effectively treated with current therapy.
"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," Selick added.